Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed133%
recruiting267%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_2

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

NCT06325696
recruitingphase_2

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

NCT05295680
completedphase_1

A Study of Oral Hymecromone and Hyaluronan Synthesis

NCT02780752

Clinical Trials (3)

Showing 3 of 3 trials
NCT06325696Phase 2

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Recruiting
NCT05295680Phase 2

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

Recruiting
NCT02780752Phase 1

A Study of Oral Hymecromone and Hyaluronan Synthesis

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3